April 02, 2018
Strongbridge Biopharma plc Announces Dosing of First Four Patients in LOGICS, a Second Global Phase 3 Study of RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome
Media
March 28, 2018
Preliminary long-term data for WTX101 in Wilson Disease accepted as a late-breaker presentation at EASL Annual Meeting
March 27, 2018
Altimmune Announces Positive Data From Its Phase 2a Study of NasoVAX Intranasal Influenza Vaccine and Provides an Update on Its Phase 1b Study of HepTcell Targeted Immunotherapy in Chronic Hepatitis B Infection
March 26, 2018
Strongbridge Biopharma plc to Host Investor and Analyst Day on April 5, 2018
March 22, 2018
Oncopeptides has completed a directed share issue of approximately SEK 314 million
March 21, 2018
BONESUPPORT™ – Positive clinical data for CERAMENT® G in infection management presented at BLRS 2018
March 20, 2018
Altimmune to Announce Year End 2017 Financial Results on March 29
March 20, 2018
Strongbridge Biopharma Announces Issuance of Patent for RECORLEV™ (levoketoconazole) for the Treatment of Cushing’s Syndrome
March 18, 2018
Strongbridge Biopharma plc Announces Presentation of New Data Demonstrating That Levoketoconazole is a Potent Inhibitor of Human Enzymes Controlling Cortisol Synthesis
March 15, 2018
Nordic Nanovector to Present Preclinical Data Highlighting the Anti-tumour Effect of Humalutin® in Three Lymphoma Models at AACR 2018
